Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 13vPnC in HIV-Infected Subjects
NCT00962780Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2010
- Primary completion
- Apr 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of Prevnar 13 in pneumococcal infection, sponsored by Pfizer. Started Mar 2010; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00962780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00962780.